Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why Generic EpiPen Is Not The Answer – Until FDA Says It Is

Executive Summary

There is no question that the concerns over Mylan’s price increases for EpiPen would deflate as rapidly as the price once an interchangeable generic is approved by FDA, but putting pressure on FDA to get a generic to market may be counterproductive.

You may also be interested in...



Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore

The latest drug development news and highlights from our FDA Performance Tracker.

Gottlieb Joins HHS Transition Team; Will Next Stop Be FDA?

Former US FDA, CMS official has been among those thought to be in the running for Trump's FDA commissioner nomination.

A Tale Of Two Committees: Which Probed EpiPen Better?

If you were an FDA official, would you prefer to be a sideshow at a contentious House committee hearing or the focus of a cordial Senate one?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel